Trial Profile
Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Early breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms LIBER
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 10 May 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.
- 04 Jun 2021 Planned End Date changed from 1 Feb 2022 to 1 Aug 2023.